...
首页> 外文期刊>Journal of Huazhong University of Science and Technology >The Roles of Four Multi-drug Resistance Proteins in Hepatocellular Carcinoma Multidrug Resistance
【24h】

The Roles of Four Multi-drug Resistance Proteins in Hepatocellular Carcinoma Multidrug Resistance

机译:四种多药耐药蛋白在肝细胞癌多药耐药中的作用

获取原文
获取原文并翻译 | 示例

摘要

The roles of multi-drug resistance protein 1 (MDR1), multi-drug resistance related protein 1 (MRP1), lung resistance protein (LRP) and breast cancer resistance protein (BCRP) in the multi-drug resistance (MDR) of hepatocellular carcinoma (HCC) were studied. By exposing HepG2 cell line to progressively increased concentrations of adriamycin (ADM), HepG2 multi-drug resistant subline (HepG2/ADM) was induced. The MDR index of HepG2/ADM was detected by using MTT. The expressions of the four MDR proteins in the three cell lines (L02, HepG2, HepG2/ADM) were investigated at mRNA and protein levels by real-time RT-PCR and Western blot respectively. Our results showed that when the ADM concentration was under 100 μg/L, HepG2 could easily be induced to be drug-resistant. The IC_(50) of the HepG2/ADM to ADM was 282 times that of HepG2. The expression of MDR1 and BCRP mRNA in HepG2/ADM cells were 400 and 9 times that of HepG2 cells respectively while there was no difference in the mRNA expressions of MRP1 and LRP. There was no difference between HepG2 and L02 cells in the mRNA expressions of the four genes. At the protein level, the expressions of MDR1, BCRP and LRP but MRP1 in HepG2/ADM were significantly higher than those of HepG2 and L02. Between HepG2 and L02, there was no difference in the expressions of four genes at the protein level. HepG2/ADM is a good model for the study of MDR. The four genes are probably the normally expressed gene in liver. The expressions of MDR1 and BCRP could be up-regulated by anti-cancer agents in vitro. The MDR of HCC was mainly due to the up-regulation of MDR1 and BCRP but MRP1 and LRP. These findings suggest they may serve as targets for the reversal of MDR of HCC.
机译:多药耐药蛋白1(MDR1),多药耐药相关蛋白1(MRP1),肺耐药蛋白(LRP)和乳腺癌耐药蛋白(BCRP)在肝细胞癌多药耐药(MDR)中的作用(HCC)进行了研究。通过将HepG2细胞系暴露于浓度逐渐增加的阿霉素(ADM)中,可诱导出HepG2多药耐药性亚系(HepG2 / ADM)。使用MTT检测HepG2 / ADM的MDR指数。通过实时RT-PCR和Western blot分别研究了三种细胞系(L02,HepG2,HepG2 / ADM)中四种MDR蛋白在mRNA和蛋白水平上的表达。我们的结果表明,当ADM浓度低于100μg/ L时,很容易诱导HepG2产生耐药性。 HepG2 / ADM到ADM的IC_(50)是HepG2的282倍。 HepG2 / ADM细胞中MDR1和BCRP mRNA的表达分别为HepG2细胞的400倍和9倍,而MRP1和LRP的mRNA表达没有差异。 HepG2和L02细胞在四个基因的mRNA表达上没有差异。在蛋白质水平上,HepG2 / ADM中MDR1,BCRP和LRP的表达明显高于HepG2和L02。在HepG2和L02之间,在蛋白质水平上四个基因的表达没有差异。 HepG2 / ADM是研究MDR的良好模型。这四个基因可能是肝脏中正常表达的基因。 MDR1和BCRP的表达可能在体外被抗癌药物上调。 HCC的MDR主要是由于MDR1和BCRP上调,但MRP1和LRP上调。这些发现表明它们可以作为逆转肝癌MDR的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号